Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort : A comparison of Lumipulse and established immunoassays
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association..
INTRODUCTION: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre-symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET).
METHODS: In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t-tau), and phosphorylated tau at site 181 (p-tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter-platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut-points optimizing concordance with 18F-florbetapir amyloid PET status (n = 63).
RESULTS: Measurements of CSF Aβ, p-tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P < .0001); those of t-tau and t-tau/Aβ42 correlated moderately (r 0.57 to 0.79, P < .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut-points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p-tau181.
DISCUSSION: The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia (Amsterdam, Netherlands) - 13(2021), 1 vom: 26., Seite e12131 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keshavan, Ashvini [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloid |
|---|
| Anmerkungen: |
Date Revised 06.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/dad2.12131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32157379X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32157379X | ||
| 003 | DE-627 | ||
| 005 | 20240306232009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/dad2.12131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1318.xml |
| 035 | |a (DE-627)NLM32157379X | ||
| 035 | |a (NLM)33598527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Keshavan, Ashvini |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort |b A comparison of Lumipulse and established immunoassays |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. | ||
| 520 | |a INTRODUCTION: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre-symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET) | ||
| 520 | |a METHODS: In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t-tau), and phosphorylated tau at site 181 (p-tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter-platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut-points optimizing concordance with 18F-florbetapir amyloid PET status (n = 63) | ||
| 520 | |a RESULTS: Measurements of CSF Aβ, p-tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, P < .0001); those of t-tau and t-tau/Aβ42 correlated moderately (r 0.57 to 0.79, P < .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut-points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p-tau181 | ||
| 520 | |a DISCUSSION: The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Lumipulse | |
| 650 | 4 | |a amyloid | |
| 650 | 4 | |a cerebrospinal fluid | |
| 650 | 4 | |a positron emission tomography | |
| 650 | 4 | |a tau | |
| 700 | 1 | |a Wellington, Henrietta |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhongbo |e verfasserin |4 aut | |
| 700 | 1 | |a Khatun, Ayesha |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Miles |e verfasserin |4 aut | |
| 700 | 1 | |a Hart, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Cash, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Coath, William |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Thomas D |e verfasserin |4 aut | |
| 700 | 1 | |a Buchanan, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Keuss, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Murray-Smith, Heidi |e verfasserin |4 aut | |
| 700 | 1 | |a Heslegrave, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Nick C |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schott, Jonathan M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia (Amsterdam, Netherlands) |d 2015 |g 13(2021), 1 vom: 26., Seite e12131 |w (DE-627)NLM248022180 |x 2352-8729 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g day:26 |g pages:e12131 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/dad2.12131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1 |b 26 |h e12131 | ||